NFKB1 and non-small cell lung carcinoma: Statistical analysis showed that the tumour volume and weight of NSCLC mice were significantly increased in CAF, CAFs-shNC group, and CAFs-shMETTL3 accelerated facilitation, after further treatment with BAY11–7085 (an inhibitor of the NF-κB pathway), the tumour volume and weight of NSCLC mice were alleviated (Figure 6a,b).